Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua New Guinea
Livingstone Tavul, Manuel W Hetzel, Albina Teliki, Dorish Walsh, Benson Kiniboro, Lawrence Rare, Justin Pulford, Peter M Siba, Stephan Karl, Leo Makita, Leanne Robinson, Johanna H Kattenberg, Moses Laman, Gilchrist Oswyn, Ivo Mueller
MALARIA JOURNAL | BMC | Published : 2018
BACKGROUND: In 2009, the Papua New Guinea (PNG) Department of Health adopted artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA-PPQ) as the first- and second-line treatments for uncomplicated malaria, respectively. This study was conducted to assess the efficacy of both drugs following adoption of the new policy. METHODS: Between June 2012 and September 2014, a therapeutic efficacy study was conducted in East Sepik and Milne Bay Provinces of PNG in accordance with the standard World Health Organization (WHO) protocol for surveillance of anti-malarial drug efficacy. Patients ≥ 6 months of age with microscopy confirmed Plasmodium falciparum or Plasmodium vivax mono-infections..View full abstract
Funding for this study was provided by the Global Fund to Fight AIDS, Tuberculosis and Malaria through a Round 8 malaria grant. AusAID provided initial funding for setting up the Alotau study site.